The 5 Alpha-Reductase System and Its Inhibitors
January 1996
in “
Dermatology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discussed the 5 alpha-reductase enzyme system, which metabolizes testosterone into dihydrotestosterone and exists in two isoforms: type 1 and type 2. Type 1 is primarily found in skin-related cells, while type 2 is located in reproductive tissues and hair follicles. The genes for these isozymes are located on chromosomes 5p and 2p. Over the past decade, various inhibitors have been developed to target 5 alpha-reductase activity. Finasteride, which targets the type 2 isozyme, was introduced for treating benign prostate hyperplasia. However, the clinical evaluation of 5 alpha-reductase inhibitors, particularly those targeting type 1, in dermatology was limited. These inhibitors, such as MK-386 and LY191704, were considered potential treatments for androgen-dependent skin disorders, including seborrhoea, acne, hirsutism, and androgenetic alopecia.
